Global Cord Blood Corporation (NYSE : CO) entered into an agreement to acquire an unknown stake in Cellenkos, Inc. from Leong Kim Chuan on April 29, 2022. As of May 9, 2022, Blue Ocean Structure Investment Company Ltd., together with its affiliates (majority shareholder of Global Cord) strongly and unreservedly opposes Global Cord's intended acquisition of Cellenkos Inc. Blue Ocean has demanded open discussions and requested Global Cord to convene an Extraordinary General Meeting ("EGM") to allow all shareholders to share their views and vote for the Proposed Acquisition. Denise Shiu of Cleary Gottlieb Steen & Hamilton LLP acted as the legal advisor to Global Cord. Yang Wang of Simpson Thacher & Bartlett LLP acted as the legal advisor to Cellenkos. On June 27, 2022, Global Cord Blood Corporation and Cellenkos, Inc. entered into an amendment thereto providing that the date by which such acquisition shall have been consummated in order to avoid the terminability thereof by either of the parties shall be extended from June 28, 2022 to July 28, 2022.

Global Cord Blood Corporation (NYSE:CO) cancelled the acquisition of an unknown stake in Cellenkos, Inc. from Leong Kim Chuan on May 20, 2022. As of June 16, 2022 104,345,365 shares out of 104,369,577, or 99.98% of the votes cast in person or by proxy, voted in favor of the Issuer refraining from the Cellenkos Transaction.